Osteomlytis
Osteomlytis
Empiric Therapy
1- Pediatric (neonate therapy a. Cefazolin
should be tailored to the b. Nafcillin, oxacillin
patient) c. Clindamycin (use if prevalence of MRSA in community is 10% or more)
d. Vancomycin (use if prevalence of MRSA and clindamycin-resistant S. aureus in
community is 10% or more)
2- Adult a. Nafcillin, oxacillin, cefazolin, ceftriaxone, clindamycin, or vancomycin
(alternatives linezolid or daptomycin)
b. Choose additional antibiotics according to patient-specific characteristics
3- Patients with sickle cell Ceftriaxone/cefotaxime or ciprofloxacin/levofloxacin (no studies assessing best
anemia empiric therapy)
4- Prosthetic joint infections
a. Debridement and retention of i. Staphylococcal: Pathogen-specific intravenous therapy plus rifampin
prosthesis or one-stage 300–450 mg twice daily for 2–6 weeks, followed by rifampin plus ciprofloxacin or
exchange of prosthesis levofloxacin for 3 months (hip, elbow, shoulder, ankle prosthesis) or 6 months
(knee prosthesis)
Therapy Length
Acute osteomyelitis: 4–6 week
Chronic osteomyelitis: 6–8 weeks of parenteral therapy and 3–12 months of oral therapy